Therapeutic advances in multiple sclerosis

JH Yang, T Rempe, N Whitmire, A Dunn-Pirio… - Frontiers in …, 2022 - frontiersin.org
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption

BA Singer, J Feng, H Chiong-Rivero - Journal of Neurology, 2024 - Springer
Multiple sclerosis (MS) is characterized by progressive neuroinflammation and
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …

In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases

Y Tasdemiroglu, RG Gourdie, JQ He - European journal of pharmacology, 2022 - Elsevier
Current medicinal treatments for diseases comprise largely of two categories: small
molecular (chemical)(eg, aspirin) and larger molecular (peptides/proteins, eg, insulin) drugs …

Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches

M Aliyu, FT Zohora, A Ceylan, F Hossain… - …, 2024 - Taylor & Francis
Background Multiple sclerosis (MS) is a central nervous system (CNS) demyelinating
autoimmune disease with increasing global prevalence. It predominantly affects females …